Does the use of paclitaxel or rapamycin-eluting stent decrease further need for coronary-artery bypass grafting when compared with bare-metal stent?
Keywords:
Angina pectoris, Coronary artery bypass, Percutaneous transluminal coronary angioplasty, Myocardial revascularization, Thoracic surgeryAbstract
CONTEXT AND OBJECTIVE: The safety and effi cacy of drug-eluting stents reduce the need for surgical revascularization. The objective of the present study was to investigate whether paclitaxel or rapamycin-eluting stent are effective in avoiding the need for coronary-artery bypass grafting. METHODS: This was a systematic review of the literature using the methodology of the Cochrane Collaboration. The type of study considered was controlled randomized trials; the type of intervention was drug-eluting or bare-metal stents; and the main outcome investigated was coronary-artery bypass grafting. RESULTS: The ten studies included in this systematic review did not show any statistically signifi cant difference between the drug-eluting stents and the bare-metal stents with regard to the outcome of coronary-artery bypass grafting (confi dence interval: 0.31 to 1.42). CONCLUSION: The surgical revascularization rate was not reduced by the use of drug-eluting stents.
Downloads
References
Betriu A, Masotti M, Serra A, et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four- year follow-up. J Am Coll Cardiol. 1999;34(5):1498-506.
Fischman DL, Leon MB, Baim DS, et al. A randomized com- parison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331(8):496-501.
Serruys PW, de Jaegere P, Kiemeneij F. A comparison of bal- loon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994;331(8):489-95.
Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part I. Circulation. 2002;106(21):2734-40.
Higgins JPT, Green S, editors. Cochrane Handbook for Sys- tematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Libray, issue 4. Chichester: John Wiley & Sons, Ltd; 2006. Available from: http://www.cochrane. org/resources/handbook/Handbook4.2.6Sep2006.pdf. Accessed in 2007 (Jul 17).
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12.
Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107(1):38-42.
Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release poly- mer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108(7):788-94.
Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel- eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350(3):221-31.
Gershlick A, De Scheerder I, Chevalier B, et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation. 2004;109(4):487-93.
Park SJ, Shim WH, Ho DS, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348(16):1537-45.
Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation. 2004;109(16):1948-54.
Morice MC, Serruys PW, Sousa JE, et al. A randomized compari- son of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773-80.
Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-23.
Schampaert E, Cohen EA, Schlüter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C- SIRIUS). J Am Coll Cardiol. 2004;43(6):1110-5.
Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362(9390):1093-9.
RevMan Analyses [Computer program]. Version 1.0 for Windows. In: Review Manager (RevMan). Version 4.2 for Windows. Copen- hagen: The Nordic Cochrane Centre, The Cochrane Collabora- tion; 2003. Available from: http://www.cc-ims.net/RevMan/faq. htm. Accessed in 2007 (Jul 17).
Toutouzas K, Colombo A, Stefanadis C. Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J. 2004;25(19):1679-87.
Hofma SH, Whelan DM, van Beusekom HM, Verdouw PD, van der Giessen WJ. Increasing arterial wall injury after long- term implantation of two types of stent in a porcine coronary model. Eur Heart J. 1998;19(4):601-9.
Danenberg HD, Welt FG, Walker M, Seifert P, Toegel GS, Edelman ER. Systematic inflammation induced by lipopolysac- charide increases neointimal formation after balloon and stent injury in rabbits. Circulation. 2002;105(24):2917-22.
Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reac- tive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol. 1998;82(4):515-8.
Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffrè PA. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol. 2000;85(1):92-5, A8.
Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 1998;98(22):2370-6.
Rajagopal V, Gurm HS, Bhatt DL, et al. Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality. Am J Cardiol. 2004;94(2):190-2.
Patti G, Di Sciascio G, D’Ambrosio A, Dicuonzo G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2002;89(4):372-6.
Hojo Y, Ikeda U, Katsuki T, et al. Release of endothelin 1 and angiotensin II induced by percutaneous transluminal coronary angioplasty. Catheter Cardiovasc Interv. 2000;51(1):42-9.
Dina JP, Feres T, Paiva AC, Paiva TB. Role of membrane po- tential and expression of endothelial factors in restenosis after angioplasty in SHR. Hypertension. 2004;43(1):131-5.
Gomes WJ, Giannotti-Filho O, Hossne NA, Catani R, Buffolo
E. Inflammatory reaction after sirolimus-eluting stent implant. Ann Thorac Surg. 2005;80(5):1903-4.
Choi SB. CYPHER coronary stents and risk of thrombosis. CMAJ. 2003;169(3):218.
Tuñón MJ, Sánchez-Campos S, Gutiérrez B, Culebras JM, González-Gallego J. Effects of FK506 and rapamycin on gen- eration of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes. Biochem Pharmacol. 2003;66(3):439-45.
Camenzind E. Safety of drug-eluting stents: a meta-analysis of first generation of drug-eluting stent programs. In: World Congress of Cardiology 2006; Sept 2-6; Barcelona; 2006.
Nordmann AJ, Camenzind E. Safety of drug-eluting stents: insights from a meta analysis. Available from: http://www. escardio.org/knowledge/congresses/CongressReports/hotline- sandctus/707009_Camenzind.htm. Accessed in 2007 (Jul 17).
